Cancer Trials Need New Endpoints For Progression, FDA Guidance Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cancer trials need new methods of measuring progression, FDA guidance says. Draft document on clinical trial endpoints for cancer drugs advocates survival as “gold standard,” but discusses value of progression assessment as potential surrogate marker